Cohort, Lymphoma
Conditions
Keywords
Lymphoma, Clinical, Cohort
Brief summary
The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.
Detailed description
Lymphoma is a common hematological malignancy. This study aims to prospectively collect clinical information on patients with lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best therapeutic strategies in the real-world population.
Interventions
No interventions need to be specified for this study
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Inclusion criteria
1. Age ≥ 16 years (including 16 years old). 2. Patients newly diagnosed with non-Hodgkin lymphoma 3. Patients who have received systematic clinical treatment. 4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Exclusion criteria
1. Patients who only receive supportive treatment. 2. Patients who cannot obtain effective evaluation data of efficacy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Baseline up to data cut-off (up to approximately 1 year) | Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Baseline up to data cut-off (up to approximately 1 year) | Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause. |
Contacts
Primary ContactWeili Zhao, MD, PhD
Backup ContactPengpeng Xu, MD
Outcome results
None listed